News & Insights

S32 co-led the $30 million financing of Puzzle, an AI-powered accounting solution, to accelerate the future of automated, real-time finance.

Once considered an unorthodox path to going public, direct listings are gaining traction as an alternative to the traditional IPO. On Wednesday, the Securities and Exchange Commission (SEC) approved a rule change, with immediate effect, that will permit companies to raise capital in a direct listing on the Nasdaq Global Select Market.

Gunderson Dettmer partners Ryan Gunderson and Jeff Thacker hosted a discussion on the benefits and considerations of raising capital from crossover funds as part of a post- IPO Summit series of workshops.

Tarsus Pharmaceuticals announces its securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing. 

Tarsus Pharmaceuticals announces its definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease.

Osanni Bio announces its $190 million Series B financing.

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP has elected six new partners, effective January 1. The elevations span the U.S. and add to the firm’s corporate and securities, venture and growth equity fund, public offerings/public companies, executive compensation and tax practices.

Chambers & Partners announced its 2015 USA Rankings and the once again Gunderson Dettmer is in the top tier in several practice areas.